Simulations Plus, Inc. (NASDAQ:SLP) developer of drug discovery and development software, is expected to report fourth quarter earnings results, after market close, on Monday 16th November 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter income of $ 0.09 per share.
Looking ahead, the full year income are expected at $ 0.47 per share on the revenues of $ 41.42 million.
Previous Quarter Performance
Simulations Plus, Inc. came out with income for the third quarter of $ 0.20 per share, from the revenue of $ 12.30 million. The quarterly earnings boosted 25.00 percent compared with the same quarter last year. Wall street analysts are predicting, SLP to report 3Q20 income of $ 0.09 per share from revenue of $ 11.21 million. The bottom line results beat street analysts by $ 0.11 or 122.22 percent, at the same time, top line results outshined analysts by $ 1.09 million or 9.72 percent.
Stock Performance
On Friday, shares of Simulations Plus, Inc. has traded high as $ 72.32 and has cracked $ 67.24 on the downward trend, reaching $ 68.09 with volume of 123.40 thousand shares.
According to the previous trading day, closing price of $ 68.09, representing a 175.00 % increase from the 52 week low of $ 26.00 and a 8.2 % decrease over the 52 week high of $ 77.89.
The company has a market capital of $ 1.36 billion and is part of the Technology sector and Health Information Services industry.
Recent Analyst recommendations
- On 16th October 2020, initiated by Raymond James at Outperform rating, with $ 95.00 target price.
Conference Call
Simulations Plus, Inc. will be hosting a conference call at 4:15 PM eastern time on 16th November 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, (213) 929-4232 Toll Free in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.simulations-plus.com
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
